Abstract:
Compulsory licenses in competition law have been criticized primarily for their detrimental effect on incentives to innovate. As dynamic efficiency including innovation leads to more economic welfare than static efficiency, it should be the preferred policy choice. However, innovation is a complex process that goes beyond merely creating incentives for the private sector. This paper by relying on the Sectorial Systems of Innovation (SSI) approach investigates the Brazilian and Indian pharmaceutical sector and demonstrates the differences in innovative capability in these two jurisdictions. Whereas, the Indian pharmaceutical industry has moved up the R&D value chain, its Brazilian counterpart, by and large, is still in the phase of imitation. The paper uses this difference to draw a prescription for compulsory licenses under competition law in Brazil and India.